| Sr.No. | Particulars | Date |
| 1- | Intimation of Schedule of Analyst/Institutional Investor Meeting | 18-Sep-23 |
| 2- | Voting Results of 31st Annual General Meeting of the Company | 29-Aug-23 |
| 3- | Outcome and Proceedings of 31st Annual General Meeting of the Company | 28-Aug-23 |
| 4- | Speech delivered by Mr. Dilip Shanghvi, Managing Director, at the 31st Annual General Meeting of the Company | 28-Aug-23 |
| 5- | Intimation of Schedule of Analyst/ Institutional Investor Meeting | 24-Aug-23 |
| 6- | Intimation of Schedule of Analyst/Institutional Investor Meeting | 16-Aug-23 |
| 7- | Disclosure – Details of Agreement (Articles of Association of the Company) | 14-Aug-23 |
| 8- | Disclosure – Details of Litigation | 14-Aug-23 |
| 9- | Intimation of Schedule of Analyst/Institutional Investor Meeting | 4-Aug-23 |
| 10 | Stock Exchange Letter Disclosure of Q1FY24 Earnings Call Audio Recording | 3-Aug-23 |
| 11- | Intimation of merger of entities in which the Company owns stake through its subsidiary | 20-Jul-23 |
| 12- | Intimation of 31st Annual General Meeting and Record date for final dividend FY2022-23 | 7-Jul-23 |
| 13- | Sun Pharma Presents Data from First in Human Phase 1 Studies of GL0034 at the American Diabetes Association 83rd Scientific Sessions | 24-Jun-23 |
| 14- | Sun Pharma Announces Health Canada Approval of WINLEVI (clascoterone cream 1%) for Topical Treatment of Acne | 19-Jun-23 |
| 15- | Stock Exchange Letter Intimation of Schedule of Analyst / Institutional Investor Meeting | 30-May-23 |
| 16- | Sun Pharma Announces China NMPA Approval For ILUMETRI (Tildrakizumab Injection) For Treatment Of Adults with Moderate-To-Severe Plaque Psoriasis | 30-May-23 |
| 17- | Sun Pharma and Philogen enter into an Exclusive Distribution, License and Supply Agreement for Commercializing specialty product, NIDLEGY™ in Europe, Australia and New Zealand | 30-May-23 |
| 18- | Update relating to earnings call | 27-May-23 |
| 19- | Non-binding indication of interest to acquire shares of Taro Pharmaceutical Industries Ltd., Israel | 27-May-23 |
| 20- | Stock Exchange Letter Intimation of Schedule of Analyst / Institutional Investor Meeting | 27-May-23 |
| 21- | Appointment of Directors | 27-May-23 |
| 22- | Stock Exchange Letter Disclosure of Q4FY23 Earnings Call Audio Recording | 26-May-23 |
| 23- | Deuruxolitinib (CTP-543) Clinical Program Update | 2-May-23 |
| 24- | Sun Pharma launches CEQUA®, a novel therapy for Dry Eye Disease in India | 25-Apr-23 |
| 25- | Update on US FDA Inspection at Mohali Facility | 23-Apr-23 |
